Leukæmi kliniske forsøg i Alabama
10 studier for Leukæmi søger deltagere på steder i Alabama.
Byer i Alabama
Officiel studietekst (engelsk)
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
- Quetzal Site 16, Birmingham
RekruttererFase 3
Alder 18 til 71 · Alle køn · Opdateret 23. sep. 2026 · NCT07504458Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
- University of Alabama - Birmingham, Birmingham
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 16. sep. 2026 · NCT06824168Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
- The University of Alabama at Birmingham, Birmingham
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 2. sep. 2026 · NCT07249346A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
- Dren Investigational Site, Birmingham
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 17. jun. 2026 · NCT05475925Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- Children's Hospital of Alabama, Birmingham
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 18. maj 2026 · NCT01790152Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies
- University of Alabama at Birmingham, Birmingham
RekruttererFase 1
Alder 18 til 75 · Alle køn · Opdateret 4. mar. 2026 · NCT07044544SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Birmingham
- Massive Bio SYNERGY-AI site, Mobile
RekruttererObservationsstudie
Alle aldre · Alle køn · Opdateret 28. okt. 2025 · NCT03452774Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant
- University of Alabama at Birmingham, Birmingham
RekruttererFase 2
Alder 18 til 75 · Alle køn · Opdateret 8. okt. 2025 · NCT06265584Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant
- University of Alabama at Birmingham, Birmingham
RekruttererFase 2
Alder 18 til 60 · Alle køn · Opdateret 8. okt. 2025 · NCT06315309Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
- University of Alabama at Birmingham, Birmingham
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 15. nov. 2024 · NCT06034275Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.